We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Roquefort Therapeutics Plc | LSE:ROQ | London | Ordinary Share | GB00BMDQ2T15 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.40 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 4.30 | 4.50 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Cmp Integrated Sys Design | -1.62M | -0.0125 | -3.52 | 5.68M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 4.40 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 26/4/2024 | 20:59 | ALNC |  EARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters Germany |
| 26/4/2024 | 07:00 | UK RNS | Roquefort Therapeutics PLC Annual Report & Financial Statements - 31 Dec.. |
| 05/4/2024 | 12:32 | ALNC | IN BRIEF: Roquefort cancels fundraise after "unusual" stock movements |
| 05/4/2024 | 07:00 | UK RNS | Roquefort Therapeutics PLC Response to Share Price Movement |
| 11/3/2024 | 11:12 | ALNC | Roquefort celebrates "significant milestones" in cancer research |
| 11/3/2024 | 07:00 | UK RNS | Roquefort Therapeutics PLC Positive Results: Midkine mRNA and STAT-6 siRNA |
| 06/2/2024 | 16:50 | ALNC | IN BRIEF: Roquefort hails further MK studies, licence talks continue |
| 06/2/2024 | 07:00 | UK RNS | Roquefort Therapeutics PLC Operations Update |
| 24/11/2023 | 07:00 | UKREG | Roquefort Therapeutics PLC Change of Auditor |
| 06/11/2023 | 12:01 | ALNC | Roquefort Therapeutics MK cell programme shows positive results |
Roquefort Therapeutics (ROQ) Share Charts1 Year Roquefort Therapeutics Chart |
|
1 Month Roquefort Therapeutics Chart |
Intraday Roquefort Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 17/4/2024 | 17:58 | Roquefort a potentially exploding 2022 bio tech stock.... | 134 |
| 22/12/2021 | 13:19 | ROQ - Watch the pumpers | 36 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-05-01 09:32:26 | 4.20 | 205,408 | 8,627.14 | O |
| 2024-05-01 08:39:04 | 4.50 | 106 | 4.77 | O |
| 2024-05-01 08:00:01 | 4.60 | 7,000 | 322.00 | UT |
| Top Posts |
|---|
Posted at 01/5/2024 09:20 by Roquefort Therapeutics Daily Update Roquefort Therapeutics Plc is listed in the Cmp Integrated Sys Design sector of the London Stock Exchange with ticker ROQ. The last closing price for Roquefort Therapeutics was 4.40p.Roquefort Therapeutics currently has 129,149,998 shares in issue. The market capitalisation of Roquefort Therapeutics is £5,682,600. Roquefort Therapeutics has a price to earnings ratio (PE ratio) of -3.52. This morning ROQ shares opened at 4.40p |
Posted at 07/4/2024 15:31 by stockhunters look at the massive delayed trades showing on roq 2.40pm exactly when the price crateredand look at the timestamps phil (now deleted posts) around 3pm selling started before he posted |
Posted at 05/4/2024 15:05 by lookinggood This is a good buy price now really. The company could have a deal land any day as they are working on this. |
Posted at 05/4/2024 07:42 by apotheki Response to Share Price MovementRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, notes recent bulletin board speculation about a placing that the Company may be undertaking. The Company recently engaged its advisers to commence a process of market soundings in relation to a potential fundraise. However, in response to incorrect bulletin board comments regarding a speculative placing price and resulting unusual share price movements, the Board has decided to not proceed with any potential placing at this time. As previously announced, Roquefort Therapeutics remains focused on completing an out-licensing agreement during the course of 2024 with potential Big Pharma partners and will update the market when a binding agreement is entered into. |
Posted at 04/4/2024 18:40 by mildredgallon Probably a dirty scammer to get price down to buy in |
Posted at 04/8/2023 16:00 by apotheki Yup ROQ are indeed looking rather good these days |
Posted at 31/7/2023 14:33 by dave4545 Cleared a seller today.I can only get 15000 at 6.5p right now, it was similar earlier but a couple of people buying at 6.25p lost patience and helped out the mm's Hopefully they will not raise funds for a few months and allow the price to recover first. |
Posted at 31/7/2023 09:53 by stockhunters "Plan to raise further funds during 2023" |
Posted at 03/3/2023 08:45 by the chairman elect which leads one to believe that potentially ROQ could go on to double or even treble in value from here |
Posted at 03/3/2023 08:44 by the chairman elect The ROQ chart looks like a coiled spring.... |
Posted at 24/1/2023 08:00 by the chairman elect Roquefort Therapeutics plc / LSE:ROQMDK Oncology Antibodies Demonstrate In-Vivo Safety Development milestone achieved Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high growth, high value oncology market is pleased to announce the ROQ-A1 and ROQ-A2 Midkine ("MDK") antibody programs, targeting metastatic breast cancer and metastatic lung cancer, have successfully demonstrated in vivo safety in pre-clinical development programs carried out by leading cancer research groups. As stated in the Company's announcement of 9 January 2023, Roquefort Therapeutics has recently signed partnership agreements and commenced pre-clinical development programs with leading academic cancer research groups at the Olivia Newton-John Cancer Research Institute (La Trobe University), Lowry Cancer Research Centre (University of New South Wales), Hawkins Laboratory Biochemistry and Genetics (La Trobe University) and the School of Medical Sciences (University of Sydney). ROQ-A1 and ROQ-A2 are the latest patented humanised antibody medicines designed by Roquefort Therapeutics to target the novel MDK target prevalent in hard-to-treat cancers. In laboratory experiments, ROQ-A1 and ROQ-A2 bind highly specifically to the MDK receptors in cancer cells to kill cancers in vitro. The MDK antibody programs targeting metastatic breast cancer and metastatic lung cancer commenced in Q4 2022 at La Trobe University, Melbourne in the Olivia Newton-John Cancer Research Institute and Hawkins Laboratory respectively and have now successfully reached the first pre-clinical drug development milestone. Metastatic breast cancer and metastatic lung cancer were chosen because of high patient mortality rates (~70% at five years) and prevalence of resistant MDK subtypes which can reduce effectiveness of existing therapies. Therefore, Roquefort Therapeutics is pleased that both ROQ-A1 and ROQ-A2 have demonstrated a good safety profile in validated in vivo models. These milestones were completed on schedule and within budget. Both MDK antibody programs will now progress into in vivo pre-clinical efficacy studies to assess cancer killing ability in primary and metastatic breast cancer and lung cancer. The Company will update the market on the results of these efficacy studies as they progress. Ajan Reginald, Chief Executive Officer of Roquefort Therapeutics, said: "We have started 2023 with significant momentum successfully completing these initial pre-clinical development milestones on schedule and within budget. The ROQ-A1 and ROQ-A2 antibodies are valuable assets that fit the established Big Pharma paradigm of treating cancer with novel antibody therapeutics. Therefore, we are pleased that both programs have shown the good safety profile that is particularly attractive for innovative cancer medicines targeting novel targets such as Midkine. Both programs will now progress rapidly into in vivo pre-clinical efficacy testing. The siRNA, MK cell therapy and Midkine oligonucleotide programs are also progressing well and are expected to complete development milestones in Q1, which we will update the market on in due course." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
